Vertex Pharmaceuticals (VRTX) says its experimental cystic fibrosis drug had met the main goal...

|About: Vertex Pharmaceuticals Inco... (VRTX)|By:, SA News Editor

Vertex Pharmaceuticals (VRTX) says its experimental cystic fibrosis drug had met the main goal of a late-stage study and will seek its approval in the second half of the year in the U.S. and Europe. Vertex does not plan to seek a sales partner for the drug, which would allow it to claim all future revenue. VRTX +16.7% premarket. (PR)